NEW
ORLEANS, June 18, 2024 /PRNewswire/ -- LongueVue
Capital ("LVC") is pleased to announce that its portfolio company
Pinnacle Clinical Research ("Pinnacle" or the "Company"), a leading
site organization founded by Dr. Stephen
Harrison and specializing in complex therapeutic areas, has
completed successful investments in Kerwin Medical Center ("KMC"),
The Cognitive and Research Center of New
Jersey ("CRCNJ"), Bellaire Clinical Research ("Bellaire"), Palmetto Clinical Research – Low
Country ("Palmetto"), and Dallas Research Institute ("DRI"). These
five additions to the Pinnacle network broaden Pinnacle's
geographic footprint to include twelve total sites across the U.S.
In addition, the KMC and CRCNJ acquisitions expand Pinnacle's
therapeutic area expertise into central nervous system ("CNS")
indications with a focus on Alzheimer's Disease ("AD"). These
acquisitions further bolster Pinnacle's value proposition as a
leader across multiple complex therapeutic indications while
providing high quality patient care, superior patient enrollment
timelines, and access to underrepresented patient populations.
"Pinnacle's rapid expansion to twelve best-in-class sites from
only three sites in 2022, coupled with its renowned physician-led
executive team, further solidifies the Company as the leading site
network focused on multiple complex therapeutic areas" said
Ryan Nagim, Managing Partner and
Head of Healthcare at LVC. He added, "We remain committed to
supporting Pinnacle's continued growth both organically and through
acquisitions."
"We are extremely excited to announce the addition of five sites
across Texas, the Southeast, and
Northeast to the Pinnacle network," said Dr. Rashmee Patil, CEO of Pinnacle. "Our goal is to
pioneer lasting treatments for complex diseases, and we are
committed to providing clinical trial opportunities to patients who
have traditionally been underserved. We believe that these new site
partnerships will enhance our mission as we broaden our scope and
clinical proficiency."
"KMC is thrilled to partner with Pinnacle and support the
Company's therapeutic area expansion," added Dr. Diana Kerwin, the founder of KMC and CNS Medical
Director of Pinnacle. "In my new role at Pinnacle, I look forward
to continuing to focus on delivering clinical excellence for
CNS-related trials as well as expanding and enhancing Pinnacle's
capabilities to support CNS studies throughout the network.
Furthermore, I am excited to welcome Dr. Michelle Papka, a friend, colleague, and founder
of CRCNJ, to the Pinnacle team as we both share a similar vision of
duplicating Pinnacle's metabolic disease state expertise in the CNS
sector."
"Pinnacle and LVC are the perfect partners to grow CRCNJ's
footprint," noted Dr. Michelle
Papka, the founder of CRCNJ and CNS Scientific Director at
Pinnacle. She added, "As Pinnacle's CNS Scientific Director, I will
work alongside Dr. Kerwin and Dr. Patil to expand Pinnacle's AD
thought leadership and enhance our sphere of influence within CNS
research. There is tremendous value in offering sponsors a scaled
network that focuses primarily on complex indications, as it
provides deeper therapeutic expertise and superior clinical
execution."
ABOUT KERWIN MEDICAL CENTER:
Headquartered in Dallas, Texas,
KMC is a leading clinical research network with an established
reputation for superior enrollment and patient care for complex CNS
studies with a focus on AD. KMC operates one site in Dallas and is currently opening another site
in South Dallas. KMC was founded
in 2019 by Dr. Diana Kerwin, a
leading Key Opinion Leader with over 20 years of experience in
Alzheimer's and dementia research, who was previously in academia
at the world-renowned Northwestern
University Cognitive Neurology and Alzheimer's Disease
Center and is now an Adjunct Assistant Professor at the
University of Texas Southwestern Medical
Center. She is Board Certified in Internal Medicine and
Geriatrics and is the principal investigator on phase I, II, and
III clinical trials for the development of therapeutics in
Alzheimer's and related dementias such as progressive supranuclear
palsy, Lewy Body dementia, and
NIH-funded studies for the prevention of Alzheimer's
dementia.
ABOUT THE COGNITIVE AND RESEARCH CENTER OF NEW JERSEY:
Headquartered in Springfield, New
Jersey, CRCNJ is a leading Northeast-based CNS clinical
research site with a focus on AD. CRCNJ operates one site in
Springfield, New Jersey and is
currently opening its second site location in Ridgewood, New Jersey. Dr. Michelle Papka, a respected thought leader in AD
who holds deep relationships with top AD sponsors, founded CRCNJ in
2009 to establish a stronghold for CNS clinical trials in the
New Jersey market. CRCNJ's
reputation for top quality care is a core driver of patient
referrals in the traditionally difficult-to-recruit CNS space.
ABOUT BELLAIRE CLINICAL
RESEARCH:
Headquartered in Houston, Texas,
Bellaire is a rapidly growing
clinical trial site with a focus on metabolic disease and
obesity-related clinical trials. Bellaire has established a reputation for
outperforming enrollments as well as serving disproportionately
impacted patient populations.
ABOUT PALMETTO CLINICAL RESEARCH - LOW COUNTRY:
Headquartered in Summerville, South
Carolina, Palmetto is a multidisciplinary clinical site
focused on metabolic disease, obesity, and CNS-related studies.
Palmetto was founded by a team of experienced physicians focused on
clinical research, including Dr. Colby
Grossman, a general practitioner with 30+ years of clinical
trial experience, Dr. Matt Carlile,
a board certified Neurologist, and Dr. Brett Van Leer-Greenberg, a board certified
Gastroenterologist.
ABOUT DALLAS RESEARCH
INSTITUTE:
Headquartered in Dallas, DRI is
focused on executing complex metabolic clinical trials in
underserved communities supporting underrepresented patient
populations.
Managing Partner Ryan Nagim was assisted by Principal
Austin Rees, Director Kent McCarty, Vice President Erin Saer, and Associates Rankin Hobbs and
Hutton Johnston.
Crosstree Capital Partners served as the buyside advisor to
LongueVue Capital for both the KMC and CRCNJ transactions.
Valcadia Healthcare Partners served as the sellside advisor for
CRCNJ.
To learn more about Pinnacle, KMC,
CRCNJ, and Palmetto, please visit:
- www.pinnacleresearch.com
- www.kerwinmedical.com
- www.thecrcnj.com
- www.palmettoclinicalresearch.com
ABOUT LONGUEVUE CAPITAL
Founded in 2001, LongueVue
Capital is a New Orleans-based
equity investment firm focused on providing transformational growth
capital to middle-market companies, drawing upon its successful 20+
year track record of partnering with entrepreneurs and management
teams to drive value creation. With over $1
billion of committed capital spanning five funds coupled
with 150+ years of combined operating and investing experience, LVC
is an ideal partner for middle-market companies at inflection
points seeking to maximize value for all stakeholders.
For more information, please visit www.lvcpartners.com, and for
media inquiries, please contact lvc@lvcpartners.com or
call (504) 293-3600.
View original
content:https://www.prnewswire.com/news-releases/pinnacle-clinical-research-accelerates-its-rapid-expansion-with-multiple-acquisitions-and-strategic-partnerships-302175647.html
SOURCE LongueVue Capital